FLASCO

FLASCO News

Home » Current News & Publications » FLASCO News
astrazeneca

FDA APPROVES NEW TREATMENT FOR PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER FOLLOWING CRT

We are pleased to inform you that the US Food and Drug Administration (FDA) has approved IMFINZI® (durvalumab) for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). There have been limited options over the past 10 years...

astrazeneca

FDA expands approval of AstraZeneca’s Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III...

The U.S. Food and Drug Administration approved Janssen’s Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant).

The U.S. Food and Drug Administration approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. “The FDA evaluates a variety of methods that measure a drug’s...

Florida Cancer Specialists Physicians Address Community Oncology Alliance National Briefing

WASHINGTON, D.C. – February 12, 2018. . . . . . . . .On Wednesday, February 7th, the Community Oncology Alliance(COA) hosted a “State of the Union” briefing at the National Press Club in Washington, DC on the current status of community oncology in the United States. Florida Cancer Specialists (FCS) physician leaders Dr. Michael...

Dr. Diane Cope Publishes Article Examining Role of Advanced Practitioner In Maintaining Patient Adherence on Oral Oncolytics

Fort Myers, FL – February 12, 2018…… Florida Cancer Specialists (FCS) Director of Nursing Diane Cope, PhD, ARNP, BC, AOCNP, was second author of a review and interventional article that examined the role of the Advanced Practitioner (AP) in maintaining compliance in patients taking oral oncolytics.  Published recently in the Journal of the Advanced Practitioner...

RECORD-SETTING “PARTY UNDER THE STARS” BENEFITS FLORIDA CANCER SPECIALISTS FOUNDATION

Lakewood Ranch, FL – February 8th, 2018…  The Florida Cancer Specialists (FCS) Foundation is proud to announce the fifth annual Party Under the Stars event, which was held on January 27th, 2018 at the Fete Catering & Ballroom, set an event record, raising more than $200,000, with all proceeds going to the Foundation. This year,...

FDA Approves abiraterone acetate in Combination with Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer

On February 7, 2018, the Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). FDA initially approved abiraterone acetate with prednisone in 2011 for patients with metastatic castration-resistant prostate cancer (CRPC) who had received prior chemotherapy, and expanded the indication...

Genentech BioOncology® Co-pay Card Assistance Program

Eligible patients pay $5 for their prescribed Genentech BioOncology®product(s)* With the Genentech BioOncology® Co-pay Assistance Program† Talk to eligible patients about enrolling today. For FDA-approved Genentech BioOncology® single and combination therapies. Terms and conditions apply. Please scroll below for details.   Features and Benefits $5 Patient pays a $5 co-pay for Genentech BioOncology®product(s)   $0...

Florida Cancer Specialists & Research Institute Welcomes Dr. J Wynn Sullivan

New Medical Oncologist Joins in Palatka Palatka, FL – February 1, 2018. . . Florida Cancer Specialists & Research Institute (FCS), the leading medical community oncology/hematology practice in the state, is pleased to announce that Medical Oncologist/Hematologist, J. Wynn Sullivan, DO has joined the statewide practice and will be seeing patients at the Palatka office located at 600...

FDA approves new treatment for certain digestive tract cancers

The U.S. Food and Drug Administration  approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera is indicated for adult...

FLASCO Response to the Humanitarian Crisis in Puerto Rico in the wake of Hurricane Maria

The Florida Society of Clinical Oncology has been actively coordinating efforts with multiple organizations, since September 20, 2017, when Hurricane Maria devastated Puerto Rico, to ensure that cancer patients are receiving appropriate cancer care both here on the U.S mainland and in Puerto Rico. On Sept 20th, the day that Hurricane Maria made land fall...

FDA Warns About Anaphylaxis, Anaphylactic Shock With Use Of Rolapitant In Patients With Cancer.

A warning about anaphylaxis, anaphylactic shock, and other hypersensitivity reactions occurring with the use of rolapitant (Varubi, Tesaro Inc) in patients with cancer has been highlighted by the US Food and Drug Administration in a MedWatch bulletin. Rolapitant is a substance/ neurokinin receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer...

FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (carfilzomib). Data added to the label demonstrated that KYPROLIS and dexamethasone (Kd) reduced the risk of death by...

FDA Commissioner Scott Gottlieb, M.D., updates on some ongoing shortages related to IV fluids

Earlier this month, we updated on the FDA’s efforts to mitigate ongoing IV saline shortages that resulted from, or were worsened by, the devastating impact of Hurricane Maria in Puerto Rico. We also provided some additional updates related to our continued efforts to help the island fully recover from this disaster. As we continue to hear concerns...

teva oncology

Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The approval was based on...

FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations

On January 12, 2018, the Food and Drug Administration granted approval to afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Approval was based on demonstration...

astrazeneca

LYNPARZA® (olaparib) Receives US FDA Approval for a New Indication

We are excited to announce on January 12, 2018, the FDA approved a new indication for the PARP inhibitor, LYNPARZA® (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy in the neoadjuvant, adjuvant...

astrazeneca

FDA approves AstraZeneca’s aparib for germline BRCA-mutated metastatic breast cancer

On January 12, 2018, the Food and Drug Administration granted regular approval to olaparib tablets (Lynparza, AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic...

FLORIDA CANCER SPECIALISTS FOUNDATION HONORS BRAD & TERRI PRECHTL AT PARTY UNDER THE STARS

Lakewood Ranch, FL – January 8th, 2018…  At the fifth annual Party Under the Stars fundraising event, the Florida Cancer Specialists (FCS) Foundation will honor Foundation Board Chair Brad Prechtl, who also serves as FCS CEO, and his wife Terri Prechtl, who is the FCS Foundation Lead Patient Support Volunteer at the Lakewood Ranch location...

Announcing a New Indication for a PERJETA

Genentech is excited to share the news of the FDA approval of PERJETA in combination with trastuzumab and chemotherapy as: ·       Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast...

2017 FLASCO Accomplishments

With the help of all of our FLASCO Members and Corporate partners, FLASCO experienced unprecedented growth in 2017. I invite you to review what was accomplished in 2017 toward the Mission of the Florida Society of Clinical Oncology.  The list of 2017 Accomplishments is included at the end of the January 11th FLASCO FLASH newsletter...

Florida Cancer Specialists & Research Institute Welcomes Dr. Gamini S. Soori

Ft. Myers, FL – January 2, 2018. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that medical oncologist Gamini S. Soori, MD, MBA, FACP, FRCP, CPE, has joined the statewide practice and will be practicing at three locations: Ft. Myers – Colonial, located at...

Florida Cancer Specialists Partners with United Healthcare Implementing Innovative Cancer Care Model

UnitedHealthcare’s Episode Payment Program Helps Expand Patient Access to Quality Care, Improve Outcomes and Reduce Costs Fort Myers, FL — January 3rd, 2018…. Florida Cancer Specialists & Research Institute (FCS), the largest independent hematology/medical oncology practice in the United States, has partnered with UnitedHealthcare to implement a cancer care model focused on quality patient care, best treatment...

Who’s Online

There are no users currently online